Alectinib艾乐替尼盐酸盐,1256589-74-8

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Alectinib Hydrochloride

CAS No. : 1256589-74-8

MCE 国际站：Alectinib Hydrochloride

产品活性：Alectinib Hydrochloride (CH5424802 Hydrochloride; RO5424802 Hydrochloride; AF-802 Hydrochloride) 是一种有效，选择性和口服的 ALK 抑制剂，其 IC₅₀ 为 1.9 nM，K_d 值为 2.4 nM (以 ATP 竞争方式)，并且还抑制 ALK F1174L 和 ALK R1275Q，其 IC₅₀ 分别为 1 nM 和 3.5 nM。Alectinib Hydrochloride 还具有有效的中枢神经系统 (CNS) 渗透能力。

研究领域：Protein Tyrosine Kinase/RTK

作用靶点：Anaplastic lymphoma kinase (ALK)

In Vitro: Alectinib (0-1000 nM; 2 hours; NCI-H2228 cells) treatment could prevent autophosphorylation of ALK in NCI-H2228 cells expressing EML4-ALK, and it also resulted in substantial suppression of phosphorylation of STAT3 and AKT.
Alectinib (0-1000 nM; 5 days; HCC827, A549, or NCIH522 cells) treatment reduces cell activity in a dose-dependent manner.

In Vivo: Alectinib (0.2-20 mg/kg; oral administration; once daily; for 11 days; SCID or nude mice bearing NCI-H2228 cells) treatment can result in dose-dependent tumor growth inhibition (EC₅₀ of 0.46 mg/kg) and tumor regression. At any dose level, no differences in body weight or gross signs of toxicity are observed.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  CNS-Penetrant Compound Library  |  Drug Repurposing Compound Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Targeted Therapy Drug Library   |  Rare Diseases Drug Library  |  Children’s Drug Library  |  EMA-Approved Drug Library  |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Membrane Protein-targeted Compound Library  |  Highly Selective Inhibitors Library  |  Serine/Threonine Kinase Inhibitor Library  |  Crizotinib  |  Lorlatinib  |  Alectinib  |  Ceritinib  |  Entrectinib  |  Brigatinib  |  Repotrectinib  |  NVP-TAE 684  |  GSK1838705A  |  MS4078  |  AZD-3463  |  Zotizalkib  |  CEP-37440  |  Ensartinib dihydrochloride  |  R-268712  |  MS4077  |  ALK-IN-1  |  ASP3026  |  ALK inhibitor 2  |  Belizatinib  |  KRCA-0008  |  UNC5293  |  ALK kinase inhibitor-1  |  Iruplinalkib  |  TL13-112  |  ALK inhibitor 1  |  HG-14-10-04  |  XST-14

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds